Limbrel

flavocoxid

(fla-vo-cox-id) flavocoxid,

Limbrel

(trade name)

Classification

Therapeutic: nonopioid analgesics
Pharmacologic: flavanoids
Pregnancy Category: UK

Indications

Dietary management of osteoarthritis; considered to be a medical food product.

Action

Anti-inflammatory and analgesic properties related to inhibition of prostaglandin synthesis by inhibiting cyclo-oxygenase (not COX-2 selective) and other mediators of inflammation.

Therapeutic effects

Decreased pain/inflammation associated with osteoarthritis, with improved mobility.

Pharmacokinetics

Absorption: Some intestinal conversion prior to absorption, remainder unknown.Distribution: Unknown.Metabolism and Excretion: Mostly metabolized by the liver.Half-life: Unknown.

Time/action profile (analgesic effect)

ROUTEONSETPEAKDURATION
POwithin 1–2 hrunknown12 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Obstetric / Lactation / Pediatric: Not recommended.Use Cautiously in: History of GI bleeding.

Adverse Reactions/Side Effects

Cardiovascular

  • ↑ BP
  • ↑ in varicose veins

Gastrointestinal

  • GI upset

Dermatologic

  • psoriasis

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Oral (Adults) 250 mg every 12 hr (up to 250 mg three times daily has been used).

Availability

Capsules: 250 mg

Nursing implications

Nursing assessment

  • Assess pain (note type, location, and intensity), range of motion, degree of swelling, and stiffness in affected joints before and periodically during therapy.

Potential Nursing Diagnoses

Chronic pain (Indications)

Implementation

  • Oral: Administer flavocoxid twice daily.

Patient/Family Teaching

  • Instruct patient to take flavocoxid as directed. Do not increase does without consulting health care professional.

Evaluation/Desired Outcomes

  • Decrease in pain and stiffness, and improved mobility in patients with osteoarthritis.